Loading
IRS2 (Insulin receptor substrate 2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Prostate cancer.
Signalling adapter protein that participates in the signal transduction from two prominent receptor tyrosine kinases, insulin receptor/INSR and insulin-like growth factor I receptor/IGF1R. Plays therefore an important role in development, growth, glucose homeostasis as well as lipid metabolism. Upon phosphorylation by the insulin receptor, functions as a signalling scaffold that propagates insulin action through binding to SH2 domain-containing proteins including the p85 regulatory subunit of PI3K, NCK1, NCK2, GRB2 or SHP2.
CIViC holds 2 clinical evidence items and 0 assertions across 1 variant, naming Capivasertib and Dual IGF-1R/InsR Inhibitor BMS-754807. Open Targets scores its association with cancer at 0.56 (direct and indirect evidence; datatypes literature 0.93, affected pathway 0.54, animal model 0.78, genetic association 0.58).
In plain words · IRS2 (Insulin receptor substrate 2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Prostate cancer.
IRS2 (Insulin receptor substrate 2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Prostate cancer.
Signalling adapter protein that participates in the signal transduction from two prominent receptor tyrosine kinases, insulin receptor/INSR and insulin-like growth factor I receptor/IGF1R.
No product in this corpus aims at IRS2 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA IRS2: RNA tissue enhanced (bone marrow 48 nTPM); blood lineage lineage enriched (granulocytes 3 nTPM); high antibody staining in 1 normal tissue. Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Colorectal cancer, Prostate cancer); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas IRS2 tissue; Open Targets ENSG00000185950 associations
First described 1997. Earliest sequence paper UniProt cites for the protein: Ogihara et al, J. Biol. Chem, 1997, "14-3-3 protein binds to insulin receptor substrate-1, one of the binding sites of which is in the phosphotyrosine binding domain". Source.
Sources: HGNC HGNC:6126 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9Y4H2 (protein name, function text, keywords and locations (REST API)); CIViC gene IRS2 (2 evidence items, 0 assertions, 1 variants; diseases: Colorectal Cancer, Prostate Cancer (GraphQL API, CC0)); Open Targets ENSG00000185950 (association with cancer (MONDO_0004992) 0.56; (GraphQL API, CC0))
Signalling adapter protein that participates in the signal transduction from two prominent receptor tyrosine kinases, insulin receptor/INSR and insulin-like growth factor I receptor/IGF1R. Plays therefore an important role in development, growth, glucose homeostasis as well as lipid metabolism. Upon phosphorylation by the insulin receptor, functions as a signalling scaffold that propagates insulin action through binding to SH2 domain-containing proteins including the p85 regulatory subunit of PI3K, NCK1, NCK2, GRB2 or SHP2. Recruitment of GRB2 leads to the activation of the guanine nucleotide exchange factor SOS1 which in turn triggers the Ras/Raf/MEK/MAPK signalling cascade. Activation of the PI3K/AKT pathway is responsible for most of insulin metabolic effects in the cell, and the Ras/Raf/MEK/MAPK is involved in the regulation of gene expression and in cooperation with the PI3K pathway regulates cell growth and differentiation. Acts a positive regulator of the Wnt/beta-catenin signalling pathway through suppression of DVL2 autophagy-mediated degradation leading to cell proliferation. Location: Cytoplasm, cytosol (UniProt). Locus 13q34 (HGNC).
RNA: tissue enhanced (bone marrow 48 nTPM), detected in all normal tissues. Blood: lineage enriched (granulocytes 3 nTPM).
Medium: Adrenal gland, Breast, Cervix, Colon, Duodenum, Gallbladder, Kidney, Liver.
No cancer stained high; medium in colorectal cancer, endometrial cancer, glioma, head and neck cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"IRS2" OR ABSTRACT:"IRS2" OR TITLE:"insulin receptor substrate 2" OR ABSTRACT:"insulin receptor substrate 2" OR TITLE:"Insulin receptor substrate 2" OR ABSTRACT:"Insulin receptor substrate 2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IRS2, not a curated reading list.